News
November 16, 2026
FDA Official Tells ObesityWeek 2026 That a Deluge of Obesity Medicine Approvals Is Coming
Dr. Raymond Soccio reviews a year of approvals, a new eye warning, and the end of the mental health warning on the leading weight loss medicines.
American Chamber of Health

WASHINGTON, November 16, 2026. The American Chamber of Health is covering ObesityWeek 2026, where Dr. Raymond Soccio of the Food and Drug Administration walked clinicians through a year of obesity medicine approvals and safety decisions, and told them the pace is about to rise sharply.
Soccio, who serves in the FDA Division of Diabetes, Lipid Disorders, and Obesity, reviewed three approvals. Oral semaglutide at 25 milligrams, sold as Wegovy tablets, was approved on December 22, 2025, with results close to the weekly injection. Injectable semaglutide at 7.2 milligrams, sold as Wegovy HD, followed on March 19, 2026, adding about 3 percent more weight loss than the standard dose. Orforglipron, sold as Foundayo, was approved in April 2026 as a small molecule medicine in the class, taken with no food or water restrictions. He said the three approvals are likely the lowest annual count for the foreseeable future, and that a deluge is coming.
One new safety signal came with the higher semaglutide dose. Changes in skin sensation appeared in 22 percent of patients at 7.2 milligrams, against 6 percent at the standard dose, and only 2 percent of those affected stopped treatment for good. The FDA has asked sponsors for more data.
On November 9, 2026, the agency added a warning for NAION, non arteritic anterior ischemic optic neuropathy, a rare eye condition, noting a possible small increase in risk with no proven mechanism. Soccio put the balance in plain terms. "So 40 versus 40,000 speaks for itself in terms of how this should affect our benefit risk assessment." About 40 patients treated prevent one major cardiovascular event, he explained, while the eye risk sits near one case in 40,000 patient years. In January 2026 the agency moved the other way, removing the suicidal ideation warning from the Saxenda, Wegovy, and Zepbound labels after its review found no increased risk.
Soccio called the STEP YOUNG results, presented at the same conference, a game changer for children under 12, for whom no obesity medicine is yet approved in the United States, and said placebo controlled trials in children now look close to inconceivable. On switching between medicines, his message was direct. Clinicians should not hold their breath for label guidance, because switching belongs in practice guidelines and individual care.
The session, The Year in Obesity Approvals and Regulatory Updates, was chaired by Dr. Jonathan Purnell of Oregon Health and Science University.
The American Chamber of Health connects healthcare leaders across the United States and covers the meetings where the field sets its direction. Connecting Healthcare, Creating Impact.
